Mark Tarnopolsky

Dr Mark Tarnopolsky

Co-Applicant

Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center

CEO/CSO Exerkine Corporation


NMD4C Involvement: Pillar 1: Preclinical Science

Email Mark

Research Interests: Mitochondrial disease, Neurogenetic diagnostics, Neurometabolic disorders, MD therapeutics, Aging/sarcopenia, Obesity

Academic web profile
Google Scholar profile

Biography

Dr. Tarnopolsky is a neuromuscular and neurometabolic clinician-scientist who received an MD and PhD (Cell Biology and Metabolism) from McMaster University.  He currently holds an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders and follows over 1500 patients with myopathies, mitochondrial disorders and other neurogenetic disorders. He has published over 500 peer reviewed papers and has an h-index of 142.  His research focuses on pharmacological, nutraceutical and exercise therapies for neuromuscular and neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria and muscle function.  He is the founder, CEO and CSO of Exerkine Corporation which is a bio-technology/nutraceutical company developing therapies for aging, obesity, muscular dystrophy and mitochondrial disorders.


Recent Publications

Assamad, D, Hansen, A, Fooks, K, Luca, S, Venkataramanan, V, Hsue, E et al.. Understanding the impact of genomic secondary findings on clinical care and patient experience: a protocol for a prospective observational study. BMJ Open. 2026.16 (3)e115821 PMID:41895807

Barreth, N, Leclair, V, Hudson, M, Bernatsky, S, Krustev, E, Moran Toro, C et al.. Soluble SIGLEC1 as a biomarker of disease activity in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2026. PMID:41872012

Ng, SY, Mikhail, AI, Mattina, SR, Lesinski, MA, Rebalka, IA, Hamstra, SI et al.. Direct AMPK Activation Confers Mutation-Independent Therapeutic Benefit in Duchenne Muscular Dystrophy. J Cachexia Sarcopenia Muscle. 2026.17 (1)e70200 PMID:41638771

Grinberg, M, Dale, B, Ramachandrannair, R, Tarnopolsky, M, Whitney, R, Ejaz, R et al.. DEGS1-Related Hypomyelinating Leukodystrophy: Four Individuals From Same Family and Review of Literature. Neurol Genet. 2026.12 (1)e200334 PMID:41404352

Murphy, A, Mak, G, Gordon, K, Grafham, GK, Provias, J, Tarnopolsky, MA et al.. Muscle mitochondrial changes in antisynthetase syndrome and other idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 2026.85 (3)285-294 PMID:41364196

Zhu, R, Liu, L, Estiar, MA, Asayesh, F, Ahmad, J, Teferra, M et al.. Loss-of-Function Variants in CPT1C: No Support for a Causal Role in Hereditary Spastic Paraplegia. Mov Disord. 2026.41 (3)779-784 PMID:41312619

Dussah, N, McKim, DA, Mah, JK, McMillan, HJ, Campbell, C, Bijelić, V et al.. Patterns of Adherence to Lung Volume Recruitment Therapy Amongst Individuals With Duchenne Muscular Dystrophy: A Secondary Analysis of the STEADFAST Randomized Controlled Trial. Pediatr Pulmonol. 2025.60 (10)e71357 PMID:41147267

Al-Mhanna, SB, Franklin, BA, Tarnopolsky, MA, Hawley, JA, Jakicic, JM, Stamatakis, E et al.. Impact of high-intensity interval training on cardiometabolic health in patients with diabesity: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025.17 (1)406 PMID:41137077

Chiarot, A, Minhas, M, de Maat, NM, Doan, J, Nilsson, MI, Hettinga, BP et al.. A Multi-Ingredient Supplement Improves Body Re-Composition, Ovarian Aging Markers, and Reproductive Success in Young and Middle-Aged Female Mice. Biomolecules. 2025.15 (9) PMID:41008565

Nederveen, JP, Nilsson, MI, Tarnopolsky, MA. Multi-ingredient supplementation for combating sarcopenia and polymorbidity. Curr Opin Clin Nutr Metab Care. 2025.28 (6)452-462 PMID:40960165

See more on PubMed